Cover Image
市場調查報告書

胃癌症檢查、治療、預防:技術及全球市場

Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets

出版商 BCC Research 商品編碼 342309
出版日期 內容資訊 英文 183 Pages
訂單完成後即時交付
價格
Back to Top
胃癌症檢查、治療、預防:技術及全球市場 Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets
出版日期: 2015年10月22日 內容資訊: 英文 183 Pages
簡介

全球胃癌診斷/篩檢及治療市場規模,2014年達2,355億美金。該市場預計從2015年的2,417億美元,到2020年達約3,183億美元,以5.7%的年複合成長率擴大。

本報告以全球胃癌症檢查、治療、預防市場為主題,提供市場概要、市場趨勢分析、臨床症狀/診斷/初期的胃癌相關詳細資訊、現在/未來的治療與診斷技術趨勢、各開發階段的開發平台評估、授權協定相關資訊,及主要企業簡介等資訊。

第1章 簡介

第2章 摘要

第3章 癌症

  • 癌症是什麼?
  • 癌症增生的原因
  • 癌症治療的策略
  • 胃癌

第4章 胃癌的簡介

  • 消化器官和癌症
  • 胃癌的全球發病率
  • 胃癌概要
  • 原因
  • 症狀
  • 治療選項
  • 關聯的癌症、概要
  • 腎臟癌的標靶治療
  • 胰臟癌
  • 摘要

第5章 胃癌的篩檢,診斷及市場

  • 篩檢
  • 篩檢方法
  • 篩檢、優點
  • 篩檢模式
  • 美國的胃癌篩檢
  • 全球胃癌篩檢

第6章 胃癌的篩檢、診斷市場

  • 篩檢
  • 診斷、預後

第7章 胃癌的治療選項

  • 目前治療

第8章 市場動態、概要

  • 標準的治療
  • 全球癌症市場趨勢
  • 開發中的醫藥品
  • 摘要

第9章 胃癌治療、預防市場規模、成長率

  • 市場:各產品類型
  • 市場:各地區

第10章 開發平台、專利、新的開發趨勢

  • 近幾年的開發趨勢、認證
  • 開發中的新藥/企業

第11章 全球癌症統計

  • 癌症趨勢
  • 新興市場
  • 摘要

第12章 企業、全球的企業

  • 企業
  • 癌症市場動態
  • 主要企業、簡介
    • BIOGEN IDEC
    • BRISTOL MYERS SQUIBB
    • ELI LILLY AND COMPANY
    • GLAXOSMITHKLINE
    • GENENTECH, INC
    • IMMUNOGEN
    • MERCK & COMPANY
    • NOVARTIS
    • PFIZER
    • ROCHE/GENENTECH
    • ONCOLYTICS
    • PACIFIC EDGE DIAGNOSTICS NZ
    • ZOVA BIOTHERAPEUTICS INC.

第13章 開發的合作夥伴

  • 研究開發的合夥協議及技術、診斷的協定

第14章 參考文件

圖表

目錄
Product Code: HLC174A

The global gastric cancer diagnostic/screening and treatment market was $235.5 billion in 2014. This market is expected to grow from $241.7 billion in 2015 to nearly $318.3 billion by 2020, with a compound annual growth rate (CAGR) of 5.7%.

This report provides:

  • An overview of the global markets for gastric cancer testing, treatment and prevention.
  • Analyses of market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.
  • Detailed information pertaining to the clinical manifestations, diagnosis, and staging of early gastric cancer.
  • Analysis of recent and projected technological trends for treatment and diagnosis.
  • Assessment of the market's pipeline broken down by phase of development.
  • Information on licensing agreements as well as research and development partnerships and agreements.
  • Comprehensive company profiles of major players in the field.

image1

REPORT SCOPE

SCOPE AND FORMAT

This report will give an overall update on gastric cancer. It will review global markets for biologic therapeutics for gastric cancer and will forecast trends for use of diagnostics, screening and cancer treatment through 2020. It will cover important therapies, biologics, diagnostics, market share, products on the market and market share by company and statistical information for types of cancers prevalent worldwide, with special emphasis on the U.S. market. Current issues and trends affecting the industry, costs and factors influencing demand will be discussed. The report covers diagnostics, therapeutics, biological products in development, biological products in clinical trials, and currently marketed and late-stage developments in biologic cancer products. In addition, this report includes:

Treatment trends and sales patterns across major cancer indications with market performance of major pharmaceutical companies.

Forecast sales of leading products across major indications to 2020.

ANALYST'S CREDENTIALS

Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 20 years of preclinical, alliance management, discovery and technology development, and marketing experience. Her strong focus areas include oncology and cardiovascular diseases with expertise in molecular and cell biology and complex cell-based biological assays including drug discovery, in vitro and in vivo screening, in vivo model development and pharmacokinetics. She has experience working with early startups.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE AND FORMAT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • RELATED BCC RESEARCH REPORTS
  • ANALYST'S CREDENTIALS
  • BCC RESEARCH WEBSITE
  • DISCLAIME

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, 2014-2020 ($ MILLIONS)

CHAPTER 3 CANCER

  • WHAT IS CANCER?
  • CAUSES OF CANCER GROWTH
  • CANCER TREATMENT STRATEGIES
    • COMMON TREATMENTS AND PROBLEMS
    • Surgery
    • Chemotherapy
    • Radiation Treatment
    • Hormone Therapy
    • Targeted Therapy
  • GASTRIC CANCER

CHAPTER 4 INTRODUCTION TO GASTRIC CANCER

  • TABLE 1 MAIN CATEGORIES OF CANCER
  • DIGESTIVE SYSTEM AND CANCER
    • ESOPHAGEAL CANCER
  • GASTRIC CANCER GLOBAL INCIDENCE
    • SUBTYPES AND CHARACTERISTICS
    • SMALL INTESTINE CANCER
  • STOMACH CANCER/GASTRIC CANCER OVERVIEW
  • TABLE 2 TYPES OF STOMACH CANCER
  • TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER
  • TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER
  • CAUSES
  • TABLE 5 RISK FACTORS
  • TABLE 6 CAUSES OF GASTRIC CANCER
  • SYMPTOMS
  • TABLE 7 SYMPTOMS
  • THERAPEUTIC OPTIONS
  • RELATED CANCERS AND OVERVIEW
    • KIDNEY CANCER
  • TARGETED THERAPIES FOR KIDNEY CANCER
  • TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER
    • SORAFENIB (NEXAVAR)
    • SUNITINIB (SUTENT)
    • TEMSIROLIMUS (TORISEL)
    • EVEROLIMUS (AFINITOR)
    • BEVACIZUMAB (AVASTIN)
    • PAZOPANIB (VOTRIENT)
    • AXITINIB (INLYTA)
  • LIVER
  • PANCREATIC CANCER
  • SUMMARY

CHAPTER 5 GASTRIC CANCER SCREENING, DIAGNOSIS AND MARKET

  • SCREENING
  • SCREENING METHODS
  • TABLE 9 GASTRIC SCREENING METHODS
  • SCREENING AND BENEFITS
  • SCREENING MODALITIES
    • Barium-Meal Gastric Photofluorography
    • Gastric Endoscopy
    • Serum Pepsinogen
  • GASTRIC SCREENING IN UNITED STATES
  • GASTRIC CANCER SCREENING WORLDWIDE
    • Conclusions

CHAPTER 6 GASTRIC SCREENING AND DIAGNOSIS MARKET

  • TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH CANCER WORLDWIDE, 2012 (THOUSANDS)
  • SCREENING
  • TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET, THROUGH 2020 ($ MILLIONS)
  • DIAGNOSIS AND PROGNOSIS
    • TESTS
    • TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER
    • IMAGING TESTS
      • Upper Gastrointestinal (GI) Series
      • Computed Tomography (CT or CAT) Scan
      • Magnetic Resonance Imaging (MRI) Scan
      • Positron Emission Tomography (PET) Scan
      • Chest X-Ray
      • Laparoscopy
      • Helicobacer Pylori
      • TABLE 13 TESTS USED TO DETECT H. PYLORI
      • Lab Tests
      • Costs
      • TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009 (MILLIONS)
    • SERUM PEPSINOGEN PREDICTS GASTRIC ADENOCARCINOMA

CHAPTER 7 GASTRIC CANCER TREATMENT OPTIONS

  • CURRENT PRACTICES
  • TABLE 15 TYPES OF STANDARD TREATMENT
    • CHEMOPREVENTION
    • ANTIOXIDANTS
    • ANTIBIOTICS
      • Non-Steroidal Anti-Inflammatory Drugs (Including Aspirin)
    • STAGING
      • Sentinel Lymph Node Mapping
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Chemoradiation
    • TARGETED THERAPY
      • Drugs Approved for Stomach (Gastric) Cancer
      • TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER
    • PROGNOSIS
    • PREVENTION
    • CHEMOTHERAPY DRUGS AND COMBINATIONS
    • TARGETED THERAPY OVERVIEW
      • Pembrolizumab
      • Ramucirumab
      • Afinitor (Everolimus)
      • Apatinib
    • FAILED DRUGS
      • Cetuximab
      • Tykerb (Lapatinib)
      • Expected Treatment Outcomes
    • GASTROINTESTINAL CANCER: MONOCLONAL ANTIBODIES
    • TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED ANTIBODY THERAPEUTICS
    • TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER TREATMENT
    • TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ MILLIONS)
    • FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ MILLIONS)
    • TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT
    • AVASTIN (BEVACIZUMAB)
    • HERCEPTIN (TRASTUZUMAB)
    • VECTIBIX (PANITUMUMAB)

CHAPTER 8 MARKET DYNAMICS AND OVERVIEW

  • TABLE 21 CANCER KEY FACTS
  • STANDARD TREATMENTS
  • GLOBAL CANCER MARKET TRENDS
  • TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLIONS OF PATIENTS)
  • FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLION PATIENTS)
  • TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND 2030 (MILLIONS)
  • FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND 2030 (MILLIONS)
  • TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015
    • GLOBAL ONCOLOGY MARKET
    • TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 ($ MILLIONS)
    • CANCER DRUGS: PAST PERFORMANCE
    • TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013 ($ MILLIONS/%)
    • EMERGING MARKETS
    • TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 ($ MILLIONS)
    • FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 ($ MILLIONS)
    • GASTRIC CANCER TREATMENT COSTS
      • Drugs Approved for Stomach (Gastric) Cancer
      • TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 ($ MILLIONS)
      • FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 ($ MILLIONS)
      • TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT
      • TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2020 ($ MILLIONS)
      • FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2014-2020 ($ MILLIONS)
      • TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
      • FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS)
      • TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
      • FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS)
  • DRUGS IN DEVELOPMENT
    • MAJOR PLAYERS
      • Roche
      • TABLE 33 PATENT EXPIRIES
      • Merck/Bristol-Myers Squibb
    • ISSUES AND TRENDS AFFECTING MARKET
  • SUMMARY

CHAPTER 9 GASTRIC CANCER TREATMENT AND PREVENTION MARKET SIZE AND GROWTH

  • MARKET BY PRODUCT TYPE
    • CYRAMZA
      • Kadcyla (ado-trastuzumab emtansine)
      • Perjeta
      • Herceptin
    • ONCOLOGY MARKET AND GROWTH
      • Leading Drugs
      • TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 ($ MILLIONS)
  • MARKET BY GEOGRAPHICAL SEGMENTS
  • TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS)
    • ONCOLOGY PIPELINE
      • U.S. Market
    • JAPAN (ASIA) MARKET
    • TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
    • FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCERMONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS)
    • TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
    • FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
    • EUROPE MARKET
    • TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
    • FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS)
    • TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
    • ASIA MARKET
    • AUSTRALIA MARKET
    • SOUTH KOREA MARKET
    • CHINA MARKET
      • Gastric Cancer Market in China
    • TAIWAN MARKET
    • SINGAPORE MARKET
    • INDIA MARKET
      • BIOMAb-EGFR
      • TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY

CHAPTER 10 PIPELINE, PATENTS AND NEW DEVELOPMENTS

  • RECENT DEVELOPMENTS AND APPROVALS
  • TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014
  • NEW DRUGS/COMPANIES IN DEVELOPMENT
    • CLINICAL TRIALS IN ONCOLOGY
    • TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009
    • FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009
      • Two New Clinical Trials for Advanced Gastric Cancer
      • TABLE 43 ROCHE - CLINICAL TRIALS
      • AZD4547
      • Pacific Edge
      • Oncolytics

CHAPTER 11 GLOBAL CANCER STATISTICS

  • CANCER TRENDS
  • TABLE 44 GLOBAL CANCER ESTIMATES, 2012 (MILLIONS)
  • TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING NON-MELANOMA SKIN CANCER)
  • TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 (MILLIONS)
  • TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012
    • TRENDS OVER TIME
    • FUTURE TRENDS 2020
    • TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%)
    • CANCER CURE AND COSTS
    • CAUSES OF RISE IN CANCER CASES
    • TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION
    • PROJECTIONS TO 2030
    • TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)
    • FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)
    • CURRENT CANCER TRENDS AND ECONOMIC BURDEN
      • The Burden of Cancer
  • EMERGING MARKETS
  • TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 (MILLIONS)
  • TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 (MILLIONS)
    • CANCER PREVALENCE AND MARKET
    • GASTRIC CANCER
    • TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012 (THOUSANDS)
    • TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER
    • AFRICA
    • ASIA
      • Cancer Prevention and Screening in Asia
    • CHINA AND JAPAN
      • Gastric H. pylori infection
        • Japan
        • China
    • MALAYSIA
    • INDIA
    • EUROPE
    • THE AMERICAS
    • TABLE 55 AMERICAS: CANCER FACTS
    • NORTH AMERICA
    • TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014
    • TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014
      • Canada
      • New Cases of Cancer in 2013
      • TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES, BY GENDER, IN CANADA, 2013 (%)
  • SUMMARY

CHAPTER 12 COMPANIES AND GLOBAL PLAYERS

  • COMPANIES
  • TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 ($ MILLIONS)
  • CANCER MARKET DYNAMICS
  • SELECTED COMPANIES AND PROFILES
    • BIOGEN IDEC
    • BRISTOL MYERS SQUIBB
    • ELI LILLY AND COMPANY
    • GLAXOSMITHKLINE
    • GENENTECH, INC
      • Hoffmann-LA Roche INC.
    • IMMUNOGEN
    • MERCK & COMPANY
    • NOVARTIS
    • PFIZER
    • ROCHE/GENENTECH
    • ONCOLYTICS
    • PACIFIC EDGE DIAGNOSTICS NZ
    • ZOVA BIOTHERAPEUTICS INC.

CHAPTER 13 PARTNERS IN DEVELOPMENT

  • RESEARCH AND DEVELOPMENT PARTNERSHIP AGREEMENTS AND TECHNOLOGY AND DIAGNOSTIC AGREEMENTS

CHAPTER 14 REFERENCES

LIST OF TABLES

  • SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, THROUGH 2020 ($ MILLIONS)
  • TABLE 1 MAIN CATEGORIES OF CANCER
  • TABLE 2 TYPES OF STOMACH CANCER
  • TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER
  • TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER
  • TABLE 5 RISK FACTORS
  • TABLE 6 CAUSES OF GASTRIC CANCER
  • TABLE 7 SYMPTOMS
  • TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER
  • TABLE 9 GASTRIC SCREENING METHODS
  • TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH CANCER WORLDWIDE, 2012 (THOUSANDS)
  • TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET, THROUGH 2020 ($ MILLIONS)
  • TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER
  • TABLE 13 TESTS USED TO DETECT H. PYLORI
  • TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009 (MILLIONS)
  • TABLE 15 TYPES OF STANDARD TREATMENT
  • TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER
  • TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED ANTIBODY THERAPEUTICS
  • TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER TREATMENT
  • TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ MILLIONS)
  • TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT
  • TABLE 21 CANCER KEY FACTS
  • TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLIONS OF PATIENTS)
  • TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND 2030 (MILLIONS)
  • TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015
  • TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013 ($ MILLIONS/%)
  • TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 ($ MILLIONS)
  • TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 ($ MILLIONS)
  • TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT
  • TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2020 ($ MILLIONS)
  • TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
  • TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
  • TABLE 33 PATENT EXPIRIES
  • TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 ($ MILLIONS)
  • TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS)
  • TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
  • TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
  • TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ MILLIONS)
  • TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
  • TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY
  • TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014
  • TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009
  • TABLE 43 ROCHE - CLINICAL TRIALS
  • TABLE 44 GLOBAL CANCER ESTIMATES, 2012 (MILLIONS)
  • TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING NON-MELANOMA SKIN CANCER)
  • TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 (MILLIONS)
  • TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012
  • TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%)
  • TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION
  • TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)
  • TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 (MILLIONS)
  • TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 (MILLIONS)
  • TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012 (THOUSANDS)
  • TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER
  • TABLE 55 AMERICAS: CANCER FACTS
  • TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014
  • TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014
  • TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES, BY GENDER, IN CANADA, 2013 (%)
  • TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, 2014-2020 ($ MILLIONS)
  • FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ MILLIONS)
  • FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLION PATIENTS)
  • FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND 2030 (MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 ($ MILLIONS)
  • FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 ($ MILLIONS)
  • FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 ($ MILLIONS)
  • FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2014-2020 ($ MILLIONS)
  • FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS)
  • FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ MILLIONS)
  • FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER- MONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS)
  • FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
  • FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2014-2020 ($ MILLIONS)
  • FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009
  • FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 (MILLIONS)
Back to Top